A Phase 2 Parallel-Group, Randomized, Double-Blind Study to Assess the Safety and Immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV-VLP], Unadjuvanted or Alum-adjuvanted)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 22 Nov 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VRC-CHKVLP059-00-VP (Primary)
Indications Chikungunya virus infections
Focus Pharmacodynamics
Sponsors PaxVax

Most Recent Events

22 Nov 2019 Interim results presented in the Emergent BioSolutions media release
22 Nov 2019 According to Emergent BioSolutions, interim results present at the American Society of Tropical Medicine and Hygiene (ASTMH) annual meeting in Maryland being held November 20 to 24, 2019
16 Apr 2019 Interim results presented in the Emergent BioSolutions media release.

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Welcome to AdisInsight